Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100473639> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3100473639 abstract "Objective To assess the safety and efficacy of camrelizumab and apatinib as combination therapy in patients with refractory gestational trophoblastic neoplasia (GTN). Methods In this open-label, single-arm, phase 2 study, eligible participants were diagnosed with recurrent/chemoresistant high-risk GTN previously received twice or more combination chemotherapy. Patients received intravenous camrelizumab 200 mg every 2 weeks and apatinib 250 mg orally taken once daily. The primary outcome was objective response rate and the secondary outcomes included safety, and one year of duration of response, and disease free survival. Results Between Aug 7, 2019, and March 18, 2020, 20 patients were enrolled. At data cut-off (May 20, 2020), all patients were able to evaluate for efficacy. The most common adverse event (AE) of any grade is neutropenia (8 [40%] patients). Grade 3/4 treatment-related AEs occurred in 60% (12/20) of the patients, and the grade 3/4 AEs included hypertension (5 [25%] patients), rash (4 [20%] patients), leukocytopenia (2 [10%] patients), elevated transaminase (2 [10%] patients), neutropenia (1 [5%] patient), and hand-foot syndrome (1 [5%] patient). One patient had treatment-related serious AE. No treatment-related death occurred in this trial. The objective response rate was 55% (11/20), and complete response rate and partial response rate was achieved in 35% (7/20) and 20% (4/20), respectively. The median progression-free survival and duration of response has not been reached. Conclusion The combination of camrelizumab and apatinib demonstrated tolerable toxicity and showed encouraging activity in patients with refractory GTN. Larger clinical trials of predictive biomarkers of response are needed." @default.
- W3100473639 created "2020-11-23" @default.
- W3100473639 creator A5038022821 @default.
- W3100473639 creator A5047153226 @default.
- W3100473639 creator A5053574015 @default.
- W3100473639 creator A5060469228 @default.
- W3100473639 creator A5064887006 @default.
- W3100473639 date "2020-11-01" @default.
- W3100473639 modified "2023-10-16" @default.
- W3100473639 title "177 Camrelizumab combined with apatinib for refractory gestational trophoblastic neoplasia: A phase 2, single-arm, prospective Study" @default.
- W3100473639 doi "https://doi.org/10.1136/ijgc-2020-igcs.154" @default.
- W3100473639 hasPublicationYear "2020" @default.
- W3100473639 type Work @default.
- W3100473639 sameAs 3100473639 @default.
- W3100473639 citedByCount "0" @default.
- W3100473639 crossrefType "proceedings-article" @default.
- W3100473639 hasAuthorship W3100473639A5038022821 @default.
- W3100473639 hasAuthorship W3100473639A5047153226 @default.
- W3100473639 hasAuthorship W3100473639A5053574015 @default.
- W3100473639 hasAuthorship W3100473639A5060469228 @default.
- W3100473639 hasAuthorship W3100473639A5064887006 @default.
- W3100473639 hasBestOaLocation W31004736391 @default.
- W3100473639 hasConcept C121332964 @default.
- W3100473639 hasConcept C126322002 @default.
- W3100473639 hasConcept C141071460 @default.
- W3100473639 hasConcept C142424586 @default.
- W3100473639 hasConcept C197934379 @default.
- W3100473639 hasConcept C2776694085 @default.
- W3100473639 hasConcept C2777063308 @default.
- W3100473639 hasConcept C2778570526 @default.
- W3100473639 hasConcept C2780668389 @default.
- W3100473639 hasConcept C2780739268 @default.
- W3100473639 hasConcept C2909463153 @default.
- W3100473639 hasConcept C31760486 @default.
- W3100473639 hasConcept C71924100 @default.
- W3100473639 hasConcept C87355193 @default.
- W3100473639 hasConcept C90924648 @default.
- W3100473639 hasConceptScore W3100473639C121332964 @default.
- W3100473639 hasConceptScore W3100473639C126322002 @default.
- W3100473639 hasConceptScore W3100473639C141071460 @default.
- W3100473639 hasConceptScore W3100473639C142424586 @default.
- W3100473639 hasConceptScore W3100473639C197934379 @default.
- W3100473639 hasConceptScore W3100473639C2776694085 @default.
- W3100473639 hasConceptScore W3100473639C2777063308 @default.
- W3100473639 hasConceptScore W3100473639C2778570526 @default.
- W3100473639 hasConceptScore W3100473639C2780668389 @default.
- W3100473639 hasConceptScore W3100473639C2780739268 @default.
- W3100473639 hasConceptScore W3100473639C2909463153 @default.
- W3100473639 hasConceptScore W3100473639C31760486 @default.
- W3100473639 hasConceptScore W3100473639C71924100 @default.
- W3100473639 hasConceptScore W3100473639C87355193 @default.
- W3100473639 hasConceptScore W3100473639C90924648 @default.
- W3100473639 hasLocation W31004736391 @default.
- W3100473639 hasOpenAccess W3100473639 @default.
- W3100473639 hasPrimaryLocation W31004736391 @default.
- W3100473639 hasRelatedWork W10386318 @default.
- W3100473639 hasRelatedWork W12229326 @default.
- W3100473639 hasRelatedWork W14327771 @default.
- W3100473639 hasRelatedWork W14747713 @default.
- W3100473639 hasRelatedWork W1618377 @default.
- W3100473639 hasRelatedWork W2548310 @default.
- W3100473639 hasRelatedWork W2731378 @default.
- W3100473639 hasRelatedWork W3657330 @default.
- W3100473639 hasRelatedWork W614665 @default.
- W3100473639 hasRelatedWork W17830138 @default.
- W3100473639 isParatext "false" @default.
- W3100473639 isRetracted "false" @default.
- W3100473639 magId "3100473639" @default.
- W3100473639 workType "article" @default.